Total Funding
44
57
Total FundingPost-IPO Equity raised
Growth Score
-31 pts
Heat Score
-4 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
73776
DiaMedica is a biopharmaceutical company that focuses on developing treatments for stroke.
- Lorianne Masuoka: Chief Medical OfficerPast Role: EpyGenix Therapeutics, Chief Medical Officer
- Ambarish Shah: Chief Technology Officer
About the Company
DiaMedica is a biopharmaceutical company that focuses on developing treatments for stroke and other vascular diseases where no current therapies are available.
The company's treatments primarily focus on on chronic kidney disease and acute ischemic stroke. Its pipeline product, DM199, is a recombinant form of human tissue kallikrein-1.
